* Applied Microbiology Inc., of Tarrytown, N.Y., and itscollaborator Astra Merck Inc., of Wayne, Pa., began a Phase I studyof nisin, an antimicrobial peptide, for treatment of peptic ulcerscaused by Helicobacter pylori. Astra Merck is a joint venturebetween Merck & Co., of Whitehouse Station, N.J., and Astra AB, ofSodertlje, Sweden.
* Houghten Pharmaceuticals Inc., of San Diego, added another $3.9million to its March 29, 1996, initial public offering (IPO) whenunderwriters Dillon, Read & Co., Hambrecht & Quist LLC andSalomon Brothers, all of New York, exercised overallotment optionsfor the purchase of 495,000 shares. Houghten generated total grossproceeds of $30.4 million through the sale of 3.8 million shares in theIPO. The company has about 12.3 million shares outstanding.
* Matrix Pharmaceutical Inc., of Fremont, Calif., raised another $9.3million in conjunction with its April 2, 1996, public offering whenunderwriters Cowen & Co., Dillon, Read & Co. Inc. and UBSSecurities LLC, all of New York, exercised overallotment options tobuy 412,500 shares. Total gross proceeds from the offering were$71.6 million through the sale of 3.16 million shares. The companyhas about 30 million shares outstanding.
* TheraTech Inc., of Salt Lake City, and its corporate partner AstraAB, of Sodertlje, Sweden, said the former's testosterone transdermalpatch was cleared for marketing in Sweden. The approval is the firstin Europe.
* VivoRx Inc. said its subsidiary, VivoRx Pharmaceuticals Inc., bothof Santa Monica, Calif., each received a $2 million investment fromPremier Inc., of Charlotte, N.C. Premier is a health care allianceformed from the merger of American Healthcare Systems, PremierHealth Alliance Inc. and the SunHealth Alliance. VivoRx andVivoRx Pharmaceuticals are developing methods of delivering livingcells and drugs.
(c) 1997 American Health Consultants. All rights reserved.